Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

BACKGROUND: Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to yield clinical benefit. We aimed to identify the mechanism(s) underlying PM resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Laoukili, Jamila, Constantinides, Alexander, Wassenaar, Emma C. E., Elias, Sjoerd G., Raats, Danielle A. E., van Schelven, Susanne J., van Wettum, Jonathan, Volckmann, Richard, Koster, Jan, Huitema, Alwin D. R., Nienhuijs, Simon W., de Hingh, Ignace H. J. T., Wiezer, René J., van Grevenstein, Helma M. U., Rinkes, Inne H. M. Borel, Boerma, Djamila, Kranenburg, Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174226/
https://www.ncbi.nlm.nih.gov/pubmed/35194192
http://dx.doi.org/10.1038/s41416-022-01742-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174226/
https://www.ncbi.nlm.nih.gov/pubmed/35194192
http://dx.doi.org/10.1038/s41416-022-01742-5

Ejemplares similares